Orchard Therapeutics plc (ORTX)
Market Cap | 71.71M |
Revenue (ttm) | 16.15M |
Net Income (ttm) | -179.13M |
Shares Out | 126.69M |
EPS (ttm) | -1.41 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 463,711 |
Open | 0.580 |
Previous Close | 0.600 |
Day's Range | 0.540 - 0.600 |
52-Week Range | 0.360 - 1.230 |
Beta | 0.69 |
Analysts | Buy |
Price Target | 3.40 (+500.71%) |
Earnings Date | n/a |
About ORTX
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinica... [Read more]
Financial Performance
In 2021, ORTX's revenue was $1.68 million, a decrease of -35.45% compared to the previous year's $2.60 million. Losses were -$144.58 million, -4.87% less than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ORTX stock is "Buy." The 12-month stock price forecast is $3.4, which is an increase of 500.71% from the latest price.
News

Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
Libmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe

Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
Global registrational trial expected to commence in the second half of 2023 Global registrational trial expected to commence in the second half of 2023

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy® (ati...

Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
Libmeldy ® product sales totaled $4.8M in Q3 and $13.0M YTD with market expansion activities continuing in Europe

Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022
BOSTON and LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the followin...

Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results
BOSTON and LONDON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on...

Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST

Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
Clinical and pre-clinical data from across the company's portfolio will be featured in four oral and six poster presentations

Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio
BOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio wil...

Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
Additional Libmeldy ® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD

Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022

Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the...

Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on ...

Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany
BOSTON and LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with Gesetzliche Krankenversicherung ...

Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
BOSTON and LONDON, April 11, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached another historic reimbursement agreement with th...

Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023

Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results
BOSTON and LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast o...

Orchard Therapeutics to Present at Multiple Investor Conferences in March 2022
BOSTON and LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the followi...

Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022
BOSTON and LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined five upcoming presentations from across its neurodegenerative por...

Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients
First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England

Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD
Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients

Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th Ann...

Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy